Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRLX301 in advanced solid tumors
ACTRN12614001292662Phase 2Terminated
- Sponsor
- Lumos Pharma, Inc.
- Start
- Dec 2014
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, open-label trial of CRLX301 in Nonhematologic neoplasms and prostate cancer (PCa) (3 arms), sponsored by Lumos Pharma, Inc. Primary endpoints: Recommended Phase 2 dose determination and Safety and tolerability at MTD/RP2D. Started Dec 2014; status: terminated.
02
Drugs
CRLX301
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12614001292662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001292662.